Qing Yun Moyeam tea leaves — subject of thousands of peer-reviewed scientific studies on Myricetin
64+ Peer-Reviewed Citations

Medical Sources

Every claim Pureami Tea Company makes is grounded in published, peer-reviewed medical literature. Below are the sources — all available free at PubMed.com.

Our Commitment to Transparency

The three names — Myricetin, DiHydroMyricetin, and Ampelopsin — all refer to the same flavonol. Search any of them on PubMed.com and you will find a substantial body of evidence. Qing Yun Moyeam produces this compound at 30–40% by plant weight, versus 3–6% for ordinary grades.

We do not cherry-pick studies. We have never made a claim not supported by the published literature. All citations below link directly to their source on PubMed or the original journal.

Medical research laboratory — Myricetin and Moyeam tea studies published on PubMed
Scientific journal alongside Qing Yun Moyeam tea — peer-reviewed research on flavonols

Qing Yun Moyeam

Ampelopsis Grossedentata — Myricetin / DiHydroMyricetin / Ampelopsin

1 studies

Dementia / Parkinson's Disease

28.
Dihydromyricetin inhibits α-synuclein aggregation, disrupts preformed fibrils, and protects neuronal cells against amyloid-induced cytotoxicity

PubMed

Dihydromyricetin was shown to block and even reverse the protein clumping (α-synuclein aggregation) that is a hallmark of Parkinson's disease, protecting brain neurons from damage.

Disclaimer: The research cited above is provided for educational purposes only and reflects the findings of independent researchers. Pureami Tea Company does not claim that Moyeam diagnoses, treats, cures, or prevents any disease. These statements have not been evaluated by the FDA. Consult your healthcare provider before making any changes to your diet or supplement regimen.